CENTESSA PHARMACEUTICALS (260) - Net Assets
Based on the latest financial reports, CENTESSA PHARMACEUTICALS (260) has net assets worth €487.35 Million EUR (≈ $569.76 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€641.76 Million ≈ $750.29 Million USD) and total liabilities (€154.41 Million ≈ $180.53 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. For live market cap and overall valuation, see CENTESSA PHARMACEUTICALS market cap and net worth.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €487.35 Million |
| % of Total Assets | 75.94% |
| Annual Growth Rate | 1.75% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 42.88 |
CENTESSA PHARMACEUTICALS - Net Assets Trend (2021–2025)
This chart illustrates how CENTESSA PHARMACEUTICALS's net assets have evolved over time, based on quarterly financial data.
Annual Net Assets for CENTESSA PHARMACEUTICALS (2021–2025)
The table below shows the annual net assets of CENTESSA PHARMACEUTICALS from 2021 to 2025. See debt-free asset ratio of CENTESSA PHARMACEUTICALS to measure how much of total assets are equity-financed.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €526.86 Million ≈ $615.96 Million |
+31.21% |
| 2024-12-31 | €401.55 Million ≈ $469.45 Million |
+69.97% |
| 2023-12-31 | €236.24 Million ≈ $276.19 Million |
-29.72% |
| 2022-12-31 | €336.17 Million ≈ $393.02 Million |
-31.61% |
| 2021-12-31 | €491.55 Million ≈ $574.68 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CENTESSA PHARMACEUTICALS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 80058100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.71 Billion | 325.15% |
| Total Equity | €526.86 Million | 100.00% |
CENTESSA PHARMACEUTICALS Competitors by Market Cap
The table below lists competitors of CENTESSA PHARMACEUTICALS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Science Applications International Corporation Common Stock
NASDAQ:SAIC
|
$5.35 Billion |
|
Taiwan Business Bank
TW:2834
|
$5.36 Billion |
|
Asseco Poland S.A.
WAR:ACP
|
$5.36 Billion |
|
Kanzhun Ltd ADR
NASDAQ:BZ
|
$5.37 Billion |
|
Bharat Dynamics Limited
NSE:BDL
|
$5.35 Billion |
|
Hisense Electric Co Ltd
SHG:600060
|
$5.34 Billion |
|
SBM Offshore N.V.
AS:SBMO
|
$5.34 Billion |
|
Samsung Securities
KO:016360
|
$5.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CENTESSA PHARMACEUTICALS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 401,545,000 to 526,863,000, a change of 125,318,000 (31.2%).
- Net loss of 197,532,000 reduced equity.
- New share issuances of 275,358,000 increased equity.
- Other factors increased equity by 47,492,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-197.53 Million | -37.49% |
| Share Issuances | €275.36 Million | +52.26% |
| Other Changes | €47.49 Million | +9.01% |
| Total Change | €- | 31.21% |
Book Value vs Market Value Analysis
This analysis compares CENTESSA PHARMACEUTICALS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.80x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 6.33x to 9.80x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €5.46 | €34.60 | x |
| 2022-12-31 | €3.54 | €34.60 | x |
| 2023-12-31 | €2.39 | €34.60 | x |
| 2024-12-31 | €3.03 | €34.60 | x |
| 2025-12-31 | €3.53 | €34.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CENTESSA PHARMACEUTICALS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1316.88%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.30x
- Recent ROE (-37.49%) is above the historical average (-56.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -64.31% | 0.00% | 0.00x | 1.32x | €-249.82 Million |
| 2023 | -63.95% | -2204.65% | 0.02x | 1.52x | €-174.71 Million |
| 2024 | -58.71% | 0.00% | 0.00x | 1.44x | €-275.91 Million |
| 2025 | -37.49% | -1316.88% | 0.02x | 1.30x | €-250.22 Million |
Industry Comparison
This section compares CENTESSA PHARMACEUTICALS's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CENTESSA PHARMACEUTICALS (260) | €487.35 Million | -64.31% | 0.32x | $5.35 Billion |
| Covestro AG (1COV) | $3.61 Billion | 9.50% | 1.92x | $11.10 Billion |
| 2invest AG (2INV) | $82.61 Million | -2.29% | 0.06x | $70.69 Million |
| COINSHARES I. LS-000247 (3TW) | $-1.41K | 0.00% | 0.00x | $472.53 Million |
| Adaptimmune Therapeutics plc (473A) | $202.98 Million | -34.55% | 0.39x | $42.94 Million |
| KINGMAN MINERALS LTD. (47A) | $1.72 Million | -14.34% | 0.35x | $251.35K |
| GENOR BIOPHARMA DL-00002 (67N0) | $1.19 Billion | -56.64% | 0.22x | $93.97 Million |
| BENO Holding AG (BENH) | $34.93 Million | 13.58% | 1.85x | $81.20K |
| Biotest Aktiengesellschaft (BIO) | $480.20 Million | 4.00% | 1.15x | $976.15 Million |
| Biotest Aktiengesellschaft (BIO3) | $225.76 Million | 7.65% | 1.38x | $656.94 Million |
About CENTESSA PHARMACEUTICALS
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hyperso… Read more